GlymaxX is designed to enable fine tuning of the fucose content of the antibody towards the originator molecule's fucose content
ProBioGen and ValenzaBio have announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology.
ProBioGen will generate a CHO-based expression system for ValenzaBio’s VB119 clinical-stage antibody. Besides the CHO.RiGHT cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology, designed to enable fine tuning of the fucose content of the antibody towards the originator molecule's fucose content. The technology is easy to use, the company claims, and its flexibility in terms of fucosylation adjustment enables its application for innovative molecules as well as for biosimilar projects.
"We are very excited to enter into this agreement with ValenzaBio", said ProBioGen's CSO Volker Sandig. "Being entrusted with such a project underlines the value of our cell line development expertise and technologies we have developed in the past decades."
Tatyana Touzova, COO at ValenzaBio, added: "The conversion to a new expression system could help ensure VB119 reaches its full potential for patients. ProBioGen possesses a unique set of experiences and technologies using their GlymaxX platform. We are privileged to partner with such an impressive group of scientists and advance a program that we believe can be an important new therapy for patients."